港股異動 | 東陽光藥(1558.HK)反彈逾10%終結4連跌
格隆匯9月10日丨此前連續4日下跌的東陽光藥(1558.HK)反彈9.84%,報4.69港元,總市值重回40億港元上方。公司核心產品可威2021年上半年貢獻收入僅為5364萬元,同比下降97%,拖累公司整體業績出現大幅降低。中金公司日前預計下半年可威銷售能有一定的恢復。公司近期共引進33個仿製藥項目,其中已經有26個獲批。而在創新產品方面,萊洛替尼針對食管癌的適應症已經進入三線臨牀。此外,公司預計兩個新藥將在2023-2024年上市。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.